Kumar Neil 4

What Happened
Neil Kumar, CEO of BridgeBio Pharma (BBIO), sold a total of 80,000 shares in open-market transactions on February 10–11, 2026 for aggregate proceeds of approximately $5.75 million. He sold 40,000 shares on Feb 10 and 40,000 shares on Feb 11 at prices ranging roughly from $70.69 to $73.25 per share across multiple trades.

Key Details

• Transaction dates: Feb 10, 2026 and Feb 11, 2026. Prices per trade ranged ~ $70.69–$73.25.
• Shares sold: 80,000 total (40,000 on Feb 10; 40,000 on Feb 11). Proceeds ≈ $5,748,664.
• Shares owned after transaction: Not specified in the excerpt provided.
• Notable footnotes: Sales were effected pursuant to a Rule 10b5‑1 trading plan adopted March 31, 2025 (prearranged plan). The filing also includes weighted‑average price ranges for groups of the sales and a disclaimer regarding beneficial ownership of certain shares. The footnotes say detailed per‑price breakdowns can be provided on request.
• Timeliness: Filing dated Feb 12, 2026; appears to be timely under Form 4 reporting rules.

Context

• These were open‑market sales executed under a 10b5‑1 plan, which are prearranged and commonly used by insiders to sell shares on a set schedule. Such sales are generally viewed as routine and do not necessarily indicate the insider’s current view of the company.
• For retail investors: purchases typically carry more weight as a bullish signal than routine, preplanned sales. This filing is informational—if you need the exact per‑trade price breakdown noted in the footnotes, the filer can provide it upon request.